Drug reference

Potassium aminobenzoate

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1163

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Peyronie’s disease | Scleroderma ▶BY MOUTH ▶Adult: 12 g daily in divided doses, to be taken after food

PDF page 1163

Contra Indications

Hyperkalaemia. severe liver damage

PDF page 1163

Cautions

Interrupt treatment during periods of low food intake (such as fasting, anorexia and nausea)—increased risk of hypoglycaemia

PDF page 1163

Safety

Interactions

→Appendix 1: potassium aminobenzoate

PDF page 1163

Side Effects

Hepatitis. hypoglycaemia

PDF page 1163

Pregnancy

Manufacturer advises avoid—limited information available.

PDF page 1163

Breast Feeding

Manufacturer advises unknown if excreted in milk—risk to infant cannot be excluded.

PDF page 1163

Renal Impairment

Manufacturer advises use with caution—increased risk of hyperkalaemia; avoid if GFR less than 45 mL/minute.

PDF page 1163

Monitoring Requirements

Manufacturer advises liver function tests should be performed monthly—discontinue immediately if elevated.

PDF page 1163

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Powder CAUTIONARY AND ADVISORY LABELS 13, 21 ▶Potaba (Cheplapharm Arzneimittel GmbH) Potassium aminobenzoate 3 gram Potaba 3g sachets | 40 sachet P £34.31 DT = £34.31

PDF page 1163

Dose text by age group

Adult

12 g daily in divided doses, to be taken after food

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1163

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Potassium aminobenzoate

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1163

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Indications And Dose

Peyronie’s disease | Scleroderma ▶BY MOUTH ▶Adult: 12 g daily in divided doses, to be taken after food

PDF page 1163

Contra Indications

Hyperkalaemia. severe liver damage

PDF page 1163

Cautions

Interrupt treatment during periods of low food intake (such as fasting, anorexia and nausea)—increased risk of hypoglycaemia

PDF page 1163

Safety

Interactions

→Appendix 1: potassium aminobenzoate

PDF page 1163

Side Effects

Hepatitis. hypoglycaemia

PDF page 1163

Pregnancy

Manufacturer advises avoid—limited information available.

PDF page 1163

Breast Feeding

Manufacturer advises unknown if excreted in milk—risk to infant cannot be excluded.

PDF page 1163

Renal Impairment

Manufacturer advises use with caution—increased risk of hyperkalaemia; avoid if GFR less than 45 mL/minute.

PDF page 1163

Monitoring Requirements

Manufacturer advises liver function tests should be performed monthly—discontinue immediately if elevated.

PDF page 1163

Dose and formulations

Medicinal Forms

PDF page 1163

Dose text by age group

Adult

12 g daily in divided doses, to be taken after food

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1163

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.